Get the Daily Brief
Latest Biotech News
CRISPR strategy exploits oncogene amplification to target tumors
Researchers at Spain’s CNIO and CIEMAT described a gene‑editing approach that selectively targets tumors with oncogene amplifications using CRISPR‑Cas9 vulnerabilities tied to genomic overload....
AI‑native pharma scales clinical development; Insilico hires oncology lead
Formation Bio described an AI‑native model that prioritizes clinical development workflows to speed and derisk drug programs; CTO Dan Neil outlined the hub‑and‑spoke asset structure and...
Rice secures ARPA‑H PRINT funding to bioprint kidney tissue
Rice University won up to $24.8 million over five years from ARPA‑H to develop bioprinted kidney tissues under the PRINT program, aiming to address the organ shortage by advancing engineered renal...
Guideline issues: therapeutic drug monitoring recommended for IBD biologics
A multidisciplinary panel released evidence‑based guidelines endorsing therapeutic drug monitoring (TDM) for biologic therapies in inflammatory bowel disease. The guideline synthesizes trial and...
Hims halts compounded Wegovy pill: regulator, industry pressure forces retreat
Hims announced it will stop offering a compounded version of Novo Nordisk’s Wegovy following legal threats and regulatory scrutiny. The telehealth company said it “decided to stop offering access”...
Bayer unveils Phase 3 win: asundexian cuts secondary stroke risk
Bayer reported Phase 3 data showing its Factor XIa inhibitor asundexian reduced the risk of secondary stroke by 26% without increasing bleeding, presenting asundexian as a potential oral...
Adaptive projects MRD boom: ClonoSeq poised for rapid revenue growth
Adaptive Biotechnologies raised its 2026 outlook on the back of accelerating adoption of its ClonoSeq minimal residual disease (MRD) assay, guiding MRD revenue to $255–$265 million and projecting...
UniQure pauses mid, high doses in Fabry gene trial after liver toxicity
UniQure said it paused mid‑ and high‑dose cohorts in its Fabry disease gene therapy study after two patients who received 4x10^13 gc/kg experienced grade 3 liver enzyme elevations. The safety...
Sanofi unpacks failed Phase 3: tolebrutinib misses in PPMS
Sanofi revealed data from a failed Phase 3 trial of the BTK inhibitor tolebrutinib in primary progressive multiple sclerosis (PPMS), detailing why the program missed endpoints and prompting...
Biotech IPOs return: Eikon, Agomab and more push public market revival
Biotech’s public markets showed renewed activity as Agomab Therapeutics and Eikon Therapeutics raised capital in recent IPOs, and industry reporting highlighted four drugmakers that went public in...
Formation Bio scales AI‑native drug development: CTO outlines clinical focus
Formation Bio detailed its AI‑native drug development model and growth strategy, with CTO Dan Neil explaining how the company applies data, software and clinical execution to accelerate assets...
Rice wins ARPA‑H backing: $24.8M grant to bioprint kidney tissue
Rice University secured up to $24.8 million from ARPA‑H to advance bioprinted kidney tissue under the PRINT program, funding a multi‑year effort to develop transplantable, vascularized renal...
CRISPR tactic exploits oncogene overload: new tumor targeting approach
A CNIO‑ and CIEMAT‑led team described an innovative gene‑editing strategy that exploits tumors with high oncogene amplification, using CRISPR‑Cas9 to selectively target cancer cells overloaded...
Phage plus antibiotic clears resistant peritonitis in mice: combo shows synergy
Researchers published Nature Communications data showing a bacteriophage‑antibiotic combination eradicated refractory peritoneal dialysis‑related peritonitis caused by Klebsiella pneumoniae in...
Hims halts compounded Wegovy sales: FDA pressure forces retreat
Telehealth company Hims & Hers announced it will stop offering a compounded version of Novo Nordisk’s Wegovy after escalating legal threats and regulatory scrutiny from U.S. authorities. Novo...
uniQure pauses higher Fabry gene therapy doses after toxicities
uniQure said it has paused mid‑ and high‑dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced dose‑limiting toxicities, including grade 3 liver enzyme...
Biotech IPOs rebound: Four drugmakers raise nearly $1 billion
Public markets saw renewed interest in biotech this week as multiple drugmakers completed IPOs, collectively raising close to $1 billion. Companies including Agomab Therapeutics and Eikon...
Priovant’s brepocitinib posts strong Phase 2 results in cutaneous sarcoidosis
Priovant Therapeutics, a Roivant spinout, reported that brepocitinib significantly outperformed placebo in a Phase 2 trial for cutaneous sarcoidosis, producing marked lesion clearance in the...
Bayer’s asundexian cuts recurrent stroke without raising bleeding
Bayer disclosed Phase 3 results showing asundexian, a Factor XIa inhibitor, reduced risk of secondary stroke by 26% without increasing clinically relevant bleeding. The firm reported the data as...
Adaptive Biotechnologies bets MRD will power 2026 growth
Adaptive Biotechnologies projected meaningful growth for its minimal residual disease (MRD) business in 2026, forecasting 20–22% revenue expansion and anticipating ClonoSeq test volume to rise...